Johnson & Johnson announces encouraging first-in-human clinical data for investigational HIV preventive vaccine
- Details
- Category: Johnson & Johnson
Johnson & Johnson has announced encouraging first-in-human clinical data for an investigational HIV-1 vaccine regimen in development at its Janssen Pharmaceutical Companies. In an oral presentation of the early stage Phase 1/2a APPROACH study at the 9th IAS Conference on HIV Science (IAS 2017),
Sandoz expands partnership with World Child Cancer, to help children access treatment in four developing countries
- Details
- Category: Novartis
Sandoz today announces the expansion of a pilot project with leading charity World Child Cancer, aimed at improving access to treatment and optimizing survival outcomes for children suffering from cancer in four developing countries. The agreement builds on an existing partnership with World Child Cancer in the Philippines, where Sandoz is funding staff training needs and helping children to access diagnosis and subsequent treatment.
Pfizer announces positive top-line results from the comparative REFLECTIONS B7391003 study for PF-06439535, a potential biosimilar to Avastin® (bevacizumab)
- Details
- Category: Pfizer
Pfizer Inc. (NYSE:PFE) has announced that the REFLECTIONS B7391003 study, a comparative, confirmatory safety and efficacy study of PF-06439535 versus Avastin®(1) (bevacizumab), met its primary objective. PF-06439535 is being developed by Pfizer as a potential biosimilar to Avastin.
U.S. Food and Drug Administration expands approval of Yervoy® (ipilimumab) to include pediatric patients 12 years and older with unresectable or metastatic melanoma
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) has expanded the indication for Yervoy ® (ipilimumab) injection for intravenous use to now include the treatment of unresectable or metastatic melanoma in pediatric patients 12 years of age and older.
Merck and Pfizer collaborate with Corning
- Details
- Category: Pfizer
Merck (NYSE: MRK), Pfizer (NYSE: PFE) and Corning Incorporated (NYSE: GLW) today announced collaborations that have enabled the modernization of pharmaceutical packaging with the introduction of Corning Valor™ Glass. This revolutionary pharmaceutical glass packaging solution enhances the storage and delivery of today's drug formulations and provides more reliable access to medicines essential to public health.
Amgen and Array BioPharma announce preclinical license and collaboration agreement in inflammation
- Details
- Category: Amgen
Amgen (NASDAQ:AMGN) and Array BioPharma (NASDAQ:ARRY) today announced a collaboration agreement for the discovery and development of novel drugs for autoimmune disorders. The undisclosed target and lead inhibitors were discovered through Array's proprietary platform that leverages Array's expertise in chemistry and early lead development.
Merck Biopharma Innovation Cup 2017
- Details
- Category: Merck Group
Merck, a leading science and technology company, announced the winners of its seventh Biopharma Innovation Cup. The winning team received €20,000 for its innovative idea around the role of Natural Killer (NK) cells in cancer immunology. The Biopharma Innovation Cup is designed to support the professional development of post-graduate students and to foster innovation from a promising new generation of academic talent.
More Pharma News ...
- Novartis confirms 5 year data for first and only fully-human IL-17A inhibitor Cosentyx® reinforcing sustained efficacy and safety profile in psoriasis
- FDA Advisory Committee votes in favor of Pfizer's MYLOTARG (gemtuzumab ozogamicin) for acute myeloid leukemia
- Novartis CAR-T cell therapy CTL019 unanimously (10-0) recommended for approval by FDA advisory committee to treat pediatric, young adult r/r B-cell ALL
- Amgen and QB3@953 announce winners of The Amgen Golden Ticket
- Positive phase III results for Roche’s emicizumab in haemophilia A published in The New England Journal of Medicine
- BESPONSA® approved in the EU for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia
- Jardiance® (empagliflozin) analysis reinforces established safety profile